A number of pharmaceutical companies have RNA-based therapeutics and vaccines in development for COVID-19. However, there are a number of safety concerns around the use of viral vectors with these therapies and the use of lipid-based nanoparticles may offer a safer alternative, says GlobalData.
Kathryn Whitney, MSc, Director of Thematic Analysis, comments: “RNA has received considerable research attention in recent years and has the potential to develop new treatments against COVID-19. Companies such as Moderna, Alnylam Pharmaceuticals and Vir Biotechnology are currently exploring the use of these nanoparticles in RNA-based vaccines and therapeutics against COVID-19.”
Viral vectors are one of the major vehicles in RNA therapy, but concerns about immunogenicity, insertional mutagenesis and biohazards exist...
Read the full text on the site GMPnews.Net